Mumbai, India
SUN PHARMA, the world's fourth-largest speciality generic pharmaceutical company and number one in India, stands out for its commitment to providing high-quality, affordable medicines to over 100 countries. With over 40 manufacturing facilities across five continents and a robust R&D infrastructure supported by about 3,000 scientists, SUN PHARMA demonstrates strong capabilities to drive innovation. The firm invests 6-8% of its annual revenues in research and development, underlining its focus on innovation.
Founded in 1983, SUN PHARMA places a significant emphasis on its workforce, fostering a culture of collective potential growth under its Employee Value Proposition entitled "Create Your Own Sunshine." This is grounded in the principles of "Better Every Day," "Take Charge," and "Thrive Together."
The firm's last significant transactional milestone was an acquisition investment on 01 December 2015, with backing from Labor Capital. Given its global footprint, robust pipeline, and proactive workforce, SUN PHARMA represents a compelling investment aligned with sustained growth and innovation in the pharmaceutical space.
Chargetrip
Catalent